View Rule

View EO 12866 Meetings Printer-Friendly Version     Download RIN Data in XML

SSA RIN: 0960-AH43 Publication ID: Fall 2014 
Title: Revised Medical Criteria for Evaluating Cancer (Malignant Neoplastic Diseases) (3757F) 
Abstract:

Sections 13.00 and 113.00, Malignant Neoplastic Diseases, of appendix 1 to subpart P of our regulations describe malignant neoplastic diseases that we consider severe enough to prevent an individual from doing any gainful activity or that cause marked and severe functional limitations for a child claiming SSI payments under title XVI. We will revise these sections to ensure that the medical evaluation criteria are up-to-date and consistent with the latest advances in medical knowledge and treatment.

 
Agency: Social Security Administration(SSA)  Priority: Other Significant 
RIN Status: Previously published in the Unified Agenda Agenda Stage of Rulemaking: Final Rule Stage 
Major: No  Unfunded Mandates: No 
CFR Citation: 20 CFR 404.1500, app 1   
Legal Authority: 42 USC 402    42 USC 405(a)    42 USC 405(b)    42 USC 405(d) to 405(h)    42 USC 405(h)    42 USC 416(i)    42 USC 421(a)    42 USC 421(i)    42 USC 423    42 USC 902(a)(5)    42 USC 1381a    42 USC 1382c    42 USC 1383    42 USC 1383b   
Legal Deadline:  None

Statement of Need:

These final regulations are necessary to update the Malignant Neoplastic Diseases listings to reflect advances in medical knowledge, treatment, and methods of evaluating malignant neoplastic diseases. The changes will ensure that determinations of disability have a sound medical basis, that claimants receive equal treatment through the use of specific criteria, and that people who are disabled can be readily identified and awarded benefits if all other factors of entitlement or eligibility are met.

Summary of the Legal Basis:

Administrative--not required by statute or court order.

Alternatives:

We considered not revising the listings and continuing to use our current criteria. However, we believe that these revisions are preferable because of the medical advances that have been made in treating and evaluating these malignant neoplastic diseases and because of our adjudicative experience.

Anticipated Costs and Benefits:

Estimated costs--low.

Risks:

None.

Timetable:
Action Date FR Cite
NPRM  12/17/2013  78 FR 76508   
NPRM Comment Period End  02/18/2014 
Final Action  06/00/2015 
Regulatory Flexibility Analysis Required: No  Government Levels Affected: None 
Small Entities Affected: No  Federalism: No 
Included in the Regulatory Plan: Yes 
Public Comment URL: www.regulations.gov  
RIN Data Printed in the FR: No 
Agency Contact:
Cheryl A. Williams
Director
Social Security Administration
Office of Medical Policy, 6401 Security Boulevard,
Baltimore, MD 21235-6401
Phone:410 965-1020
Email: cheryl.a.williams@ssa.gov

Mark Kuhn
Social Insurance Specialist
Social Security Administration
Office of Medical Listings Improvement, 6401 Security Boulevard,
Baltimore, MD 21235-6401
Phone:410 966-6109

Brian Rudick
Social Insurance Specialist, Regulations Writer
Social Security Administration
Office of Regulations and Reports Clearance, 6401 Security Boulevard,
Baltimore, MD 21235-6401
Phone:410 965-1483
Email: brian.rudick@ssa.gov